Kornimate/medical-research-clean huggingface dataset:
laser ablation after stereotactic radiosurgery

Conditions: Metastatic Brain Tumors; Progression; Radiation Necrosis; Quality of Life

Summary: the need for new technologies and devices in the field of neurosurgery is well established. in april 2013, fda cleared neuroblate™ system, minimally invasive robotic laser thermotherapy tool. it employs a pulsed surgical laser to deliver targeted energy to abnormal brain tissue caused by tumors and lesions. this post-marketing, multi-center study will include patients with metastatic tumors who failed stereotactic radiosurgery and are already scheduled for neuroblate procedure. the study will collect clinical outcome, quality of life (qol) and, where feasible, healthcare utilization data for publication.


Eligibility criteria:
key inclusion criteria: 1. patient has signed and received a copy of the informed consent form 2. patient may have up to 3 target supratentorial metastatic lesions previously treated with stereotactic radiosurgery, with radiological evidence of progression, pseudoprogression or radionecrosis. subject may have additional non target lesions present as long as they are not expected (in investigator's judgment) to contribute to symptomatology during the course of the study or confound interpretation of radiological and clinical measures. 3. karnofsky performance status (kps) ≥ 60. key exclusion criteria: 1. females who are pregnant, breast feeding, or plan to become pregnant in the 6 months following index procedure. 2. leptomeningeal metastases. 3. uncontrolled infectious process. 4. uncontrolled hypertension (systolic \>180 mm hg), angina pectoris, or cardiac dysrhythmia, or recent (within 6 weeks) history of intracranial hemorrhage. 5. serious infection, immunosuppression or concurrent medical condition (chronic or acute in nature) that may prevent safe participation or ability to meet follow-up requirements. 6. abnormal absolute neutrophil count (anc\<1000/mm), platelets (\<100,000/mm) or the administration of antiplatelet agents (aspirin, plavix etc) or anticoagulation within 7 days prior to treatment. 7. inadequate bone marrow, liver and renal function (e.g., total bilirubin \> 1.5 x uln; ast, alt \> 2.5 x uln; alkaline phosphatase \> 2.5 x uln; serum creatinine \> 1.5 x uln).

Keywords: metastatic brain tumors progression radiation necrosis quality of life
integrating malaria vaccine with seasonal malaria chemoprevention in west africa

Conditions: Malaria Vaccine

Summary: this is a multi-site, multi-disciplinary, phase-4 two-arm cluster-randomised non-inferiority trial in burkina faso and mali to evaluate the eﬀectiveness and real-life impact of a novel integrated delivery strategy of the r21 malaria vaccine alongside smc among children in areas with highly seasonal malaria transmission. in this study, a cluster is defined as the catchment area of a health centre. clusters will be randomised to receive either year-round age-based routine epi vaccination for children aged 5-36 months ("routine epi vaccination") in burkina faso or an annual campaign of the 3-dose primary series in children aged 5-36 months prior to the malaria season and smc delivery (''routine pre-smc vaccination'') in mali versus an annual campaign of the 3-dose primary series aligned with smc distribution in children aged 3-59 months ("integrated smc vaccination") in each country. eﬀectiveness will be assessed in terms of clinical malaria, vaccine coverage, acceptability, feasibility, and cost-eﬀectiveness. malaria incidence will be determined using routine surveillance activities for clinical malaria detection and reporting in each country. cross-sectional surveys will be conducted to determine the prevalence of parasitaemia in the communities. in addition, the acceptability, feasibility, coverage and cost-effectiveness of the different delivery systems of r21/matrix-m will be assessed.


Eligibility criteria:
inclusion criteria: control arms : * children aged 5-36 months in burkina faso and mali at the time of first study vaccination; * resident in the catchment area of a health centre assigned to the control arm; * willingness to comply with the study procedures; * written informed consent from parent/guardian. intervention arms : * children aged 3-59 months at the time of first study vaccination; * resident in the catchment area of a health centre assigned to the intervention arm; * willingness to comply with the study procedures; * written informed consent from parent/guardian. exclusion criteria: 1. history of allergic disease or reactions likely to be exacerbated by any component of the vaccines; 2. any history of anaphylaxis in relation to vaccination; 3. known chronic illness; 4. any other significant disease, disorder or situation which, in the opinion of the investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial; 5. history of vaccination with another malaria vaccine. -

Keywords: malaria cps pediatric vaccine r21
study of glasgow coma scale in neurological patients

Conditions: Individuality

Summary: the assessment of the level of consciousness in patients admitted to intensive care units (icu) can be complicated because the variables that are evaluated can be interpreted in a different way by different observers. the main objective is to determine interobserver agreement of the glasgow coma scale (gcs) among icu nurses and assess whether professional experience change the results. secondary objective: to determine interobserver agreement in each of the three components (motor response, verbal and eye opening) of the gcs

prospective observational study conducted in a multi-unit 18 beds, neurological and / or neurosurgical patients are included. variables: demographic, reason for admission, overall and its components gcs. the neurological assessment was performed by a minimum of 3 nurses. one of them applied algorithm and evaluation technique and all agreed independently valued response to stimuli. interobserver agreement measured by the intraclass correlation coefficient (icc) with confidence interval (ci) of 95%. this study was approved by the ethics committee of clinical trials hospital.

Eligibility criteria:
inclusion criteria: * neurologic patients exclusion criteria: * pregnants, under-ages
sarcopenia and balance in postmenopausal osteoporosis

Conditions: Osteoporosis, Postmenopausal; Balance; Distorted; Sarcopenia

Summary: the study was performed on 53 postmenopausal osteoporosis patients who presented to our osteoporosis outpatient clinic. following written informed consent, patients were evaluated for sarcopenia according to the sarcopenia algorithm proposed by the european working group on sarcopenia in older people (ewgsop). algorithm parameters were walking speed, muscle strength and muscle mass measurements. we used timed up and go test (tug) for evaluation of walking speed, jamar hand dynamometer for muscle strength assessment, and calf circumference for muscle mass measurement. balances of the patients were evaluated with berg balance scale (bbs) and functional skills were evaluated with the timed up and go test (tug). other clinical parameters (age, body mass index (bmi), 25ohvitd level, menopause age, fall within the last year, fracture history, history of fracture in mother) were questioned.

the study was performed on 53 postmenopausal osteoporosis patients who presented to our osteoporosis outpatient clinic. following written informed consent, patients were evaluated for sarcopenia according to the sarcopenia algorithm proposed by the european working group on sarcopenia in older people (ewgsop). algorithm parameters were walking speed, muscle strength and muscle mass measurements. we used timed up and go test (tug) for evaluation of walking speed, jamar hand dynamometer for muscle strength assessment, and calf circumference for muscle mass measurement. balances of the patients were evaluated with berg balance scale (bbs) and functional skills were evaluated with the timed up and go test (tug). other clinical parameters (age, body mass index (bmi), 25ohvitd level, menopause age, fall within the last year, fracture history, history of fracture in mother) were questioned. spss 22.0 program will be used for statistical evaluation and correlation analysis will be done.

Eligibility criteria:
inclusion criteria: * having postmenopausal osteoporosis * no other disease that can cause balance disorder * volunteer participation in the study exclusion criteria: * to have a disease that will cause balance disorder, * having understanding problem to prevent communication with the patient, * the lack of motor function to the balance device.

Keywords: osteoporosis sarcopenia balance disorder
the effects of sphenopalatine ganglion acupuncture on nasal function

Conditions: Healthy

Summary: sphenopalatine ganglion (spg)-acupuncture has been shown to exhibit distinct effects in treatment of nasal inflammatory disease, but the mechanisms remain largely unknown. investigators aimed to assess the effects of spg acupuncture for nasal ventilation function and autonomic nervous system in health volunteers. the randomized, double-blind, controlled clinical trial enrolled healthy volunteers.healthy subjects were randomly assigned to either active spg-acupuncture group or sham-acupuncture group. all subjects were assessed for self-reported nasal ventilation, nasal patency (nasal airway resistance (nar) and nasal cavity volume (nvc)), exhaled nasal nitric oxide (nno) before and after acupuncture. meanwhile, in order to explore underlying mechanisms of spg acupuncture, the changes in neuropeptides (substance p (sp), vasoactive intestinal peptide (vip) and neuropeptide y (npy)) in nasal secretions were investigated at baseline, 30 minutes, 2 hours, and 24 hours after acupuncture.


Eligibility criteria:
inclusion criteria: * non-smoking volunteers * without history of nasal disease (allergic rhinitis, sinusitis, nasal polyps, nasal septum deviation and history of nose surgery) or lung disease (asthma, chronic obstructive pulmonary disease and fibrosis) * free of upper and lower respiratory tract infections for at least 4 weeks before beginning the study. * negative skin prick test for allergy exclusion criteria: * had received acupuncture within the last four weeks before the start of the study * no history of diabetes mellitus, autonomic neuropathy, coronary heart disease or hypertension.

Keywords: acupuncture sphenopalatine ganglion nasal ventilation neuropeptides
the effect of prior learning on word learning

Conditions: Language Development Disorders

Summary: the goal of this clinical trial is to compare two treatment conditions for late talking toddlers. in 8 weeks of word learning treatment, toddlers will be taught words that sound more like the words they already know or sound less like the words they already know. the investigators see which group learns more, to understand if choosing words that let children use the knowledge they already have helps with learning.

late talking toddlers will be assigned to be in the more familiar sounds condition or the less familiar sounds condition. both groups will receive 8 weeks of vocabulary acquisition and usage for late talkers (vault) word learning treatment (2x/week for 30 minutes per session) using their words. the investigators will compare learning within children (taught words v. control words that are not explicitly taught) to make sure the learning that is happening is due to the treatment and not just maturation. the investigators will compare across groups to see if the group treated with more familiar sounding words learns more than the group treated with less familiar sounding words.

Eligibility criteria:
inclusion criteria: * native english speaking * pass pure tone hearing screening or medical report of normal hearing * 2-3 years of age at start of study * mcdi expressive scales \<10th percentile exclusion criteria: * parental reports of other diagnoses * enrolled in concurrent treatment elsewhere * nonverbal iq \<75 as measured by the bayley scales * parents unable to consistently bring child to treatment sessions

Keywords: late talkers
cellular microrna signatures in multiple sclerosis

Conditions: Multiple Sclerosis, Relapsing-Remitting

Summary: a limited number of studies on microrna expression variation in immune cells have been reported in relapsing-remitting multiple sclerosis (rrms). these studies have been performed mostly on a small scale and on whole blood mononuclear cells (pbmc). in a number of cases, rrms progresses to a severe secondary neurodegenerative form. in this context, it is important to look for biomarkers that could indicate the pathogenic activity of certain immune cell subpopulations.

sep-mir is a prospective, single-center, descriptive study. participants will be recruited among adult patients with rrms coming for a follow-up consultation in the neurology department, nervous system diseases pole, at the hôpital pitié - salpêtrière (paris). as this is a descriptive study, the recruitment of 20 participants (10 patients with relapsing-remitting ms and 10 patients with relapsing-remitting ms) should meet the objectives of this study. a 50 ml blood sample will be obtained from each participant and several clinical data regarding their pathology will be collected.

Eligibility criteria:
inclusion criteria: * caucasian population * female and male individuals with an f/m ratio of 2-4/1 * individuals with rrms according to the 2010 mcdonald criteria for less than 15 years, with edss 1-6, in remission or relapse * participant's condition compatible with a maximum of 50 ml of blood collection * persons affiliated with a social security plan. exclusion criteria: * ms treatment with steroidal anti-inflammatory drugs, immunomodulators or immunosuppressants within 2 months prior to blood collection * persons with acute and chronic infectious disease, autoimmune/inflammatory disease or cancer other than ms * pregnant or lactating women * be under guardianship, * be deprived of liberty by judicial or administrative decision, or be under legal protection.

Keywords: inflammation ifn-beta autoimmunity gene regulation
strategic intervention on preserving motor function during awake craniotomy

Conditions: Glioma

Summary: this study aims to compare the motor functions after traditional or a new surgical plan during awake glioma resection surgery.

this study concentrates on patients with type iii motor area glioma. in the awake surgery, the investigators compare the new surgical plan, which the investigators use a monopolar stimulator to determine and retain the tumor margin within 5mm from the posterior limb of the inner capsule. for the traditional surgical plan, the investigators use bipolar stimulator according to the current standard surgery plan. after the positive points are identified by stimulator, the positive points are retained in order to preserve the motor function while all the non-positive points of the tumor are resected. this study is designed to determine whether the new surgical plan is more suitable for type iii motor area glioma patients.

Eligibility criteria:
inclusion criteria: * 1)age ≥ 18 years \<65 years; 2)histopathological diagnosis with low grade glioma (lgg) according to the 2021 world health organization (who) criteria; 3)patients with primary type iii (the tumor is less than 5 mm away from the posterior limb of the inner capsule) supratentorial glioma in the motor area confirmed by radiologist; 4)no history of biopsy, radiotherapy, or chemotherapy. exclusion criteria: * 1) patients who received radiotherapy, chemotherapy or anti-tumor biotherapy within 1 month before the test; 2) patients who received immunotherapy within 3 months before the test; 3) patients who participated in other clinical trials within 3 months before the test ; 4) patients with a history of severe allergies or allergies; 5) pregnancy, breastfeeding or those who are fertile but have not taken contraceptive measures; 6) have other serious medical diseases or severe uncontrollable infections; 7) drugs and drugs abuse, long-term alcoholism and aids patients; 8) those who have uncontrollable seizures, or lose self-control due to mental illness.

Keywords: glioma awake craniotomy motor function recovery
platelet-activation and optimal inhibition in patients with atrial fibrillation undergoing left atrial appendage occlusion

Conditions: Atrial Fibrillation

Summary: the popular-laao registry is an open-label observational prospective registry to investigate hemostatic processes following left atrial appendage occlusion.

this is an open-label observational prospective registry. the aim is to develop a better understanding of coagulation, platelet reactivity and prothrombotic factors in the first months after left atrial appendage occlusion, as occurrence of device-related thrombus and optimal postprocedural management remain a challenge after laao. the study population will consist of patients with non-valvular atrial fibrillation (af) at risk for cardio-embolic stroke scheduled for left atrial appendage occlusion. in these patients, blood samples for coagulation and platelet reactivity testing will be taken, which will be gathered prior to the procedure and 1 day, 14 days, 3 months and 6 months after the procedure. data will be analyzed longitudinally and between groups based on patient characteristics.

Eligibility criteria:
inclusion criteria: * the subject is aged 18 years or older * the subject is accepted/scheduled for left atrial appendage occlusion * the subject has a cha₂ds₂-vasc score ≥2 (male) or ≥3 (female) * the subject or legal representative is able to understand and is willing to provide written informed consent to participate in the trial. exclusion criteria: * unable or unwilling to return for required follow-up visits and examinations * mechanical heart valves or valvular disease requiring surgery or interventional procedure * ongoing major bleeding or complicated or recent (\<72hours) major surgery * known large oesophageal varices or decompensated liver disease (unless a documented positive opinion of a gastro-enterologist) * severe thrombocytopenia (\<50,000/ml) * high likelihood of being unavailable for follow-up or psycho-social condition making study participation impractical. * woman with child bearing potential who do not use an efficient method of contraception. * positive serum or urine pregnancy test for woman with child bearing potential * pregnancy or within 48 hours post-partum * unsuitable laa anatomy for occlusion or thrombus in the laa at the time of procedure * contraindications or unfavourable conditions to perform cardiac catheterization or transesophageal echocardiography (tee) * atrial septal malformations, atrial septal defect or a high-risk patent foramen ovale that may cause thrombo-embolic events * atrial septal defect repair or closure device or a patent foramen ovale repair or any other anatomical condition as this may preclude an laao procedure * mitral valve regurgitation grade 3 or more * aortic valve stenosis (ava\ 50 mmhg) or regurgitation grade 3 or more * planned carotid endarterectomy (cea) for significant carotid artery disease * life expectancy of less than 1 year

Keywords: left atrial appendage occlusion device-related thrombus platelet reactivity coagulation activation
evaluation of a training program for homozygous sickle cell disease patients

Conditions: Sickle Cell Hemoglobin C Disease; Hemoglobin S Disease

Summary: sickle cell disease (scd) is the most frequent inherited disease in the world. literature reports that scd patients display intolerance to exercise, important muscle weakness and profound remodeling of skeletal muscle including amyotrophy and rarefied microvascular network. because strenuous exercise induces acidosis, hemorheological alterations, endothelial activation and oxidative stress, it constitutes a potential triggering factor of sickling and vaso-occlusive crisis. as a consequence, physical activity is usually discouraged in patients with scd. however, moderate and regular physical activity seems to be not only safe but also beneficial for scd patients.

besides, endurance training is known to induce moderate muscle hypertrophy and increase microvascular network. therefore, adapted, moderate and regular physical activity appears as a potential strategy able to improve muscle function, decrease symptoms of the disease and improve autonomy and quality of life of patients with scd. however, it remains necessary to define the modalities of exercise therapy in scd and to objectively evaluate the risks, limitations and gains on physical ability, muscle function and quality of life in patients with scd.

Eligibility criteria:
inclusion criteria: * sickle cell disease patient (hbss or hbs-βthal0), * affiliated to a health security program, * consent form signed, * patients in stabilized state at the onset of the experiment: at least one month after an acute adverse event and at least 3 months after a blood transfusion. exclusion criteria: * patients whom adhesion/compliance to the protocol appears uncertain, * patient involved in another clinical trial or within the exclusion period of a previous clinical trial, * patients known to be affected by a chronic inflammatory or infectious pathology, * patients having an intercurrent infection, especially inflammatory, unsolved since less than one month, * patients with clinical signs of heart failure or hospitalized for cardiac decompensation during the past 12 months, * patients with left ventricular ejection fraction \ 2.5 m/s, atrial fibrillation, ventricular rhythm disorders during exercise, left ventricular hypertrophy (septal to lateral wall thickness ≥ 10 mm), significant valvulopathy, established coronary disease, uncontrolled hypertension, * patients with a treatment against cardiac arrhythmia or altering sino-atrial node activity (beta-blockers, atropine, sympathomimetic agents...), * patients under anti-coagulant treatment, * patients with pacemaker or defibrillator, * body mass index (bmi) \> 35, * patients with hip osteonecrosis, * patients with cerebral vasculopathy or history of stroke (cerebrovascular attack) with epilepsy, * pregnant or lactating patients, * homeless patients, * patients with the inability to understand the aims,

Keywords: sickle cell hemoglobin c disease sports training hemoglobin s disease lactate